<![CDATA[Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC]]>

Regulatorydurvalumabenfortumab vedotinPositive

AI Analysis

Summary

The FDA granted priority review to durvalumab plus enfortumab vedotin for perioperative treatment of cisplatin-ineligible muscle-invasive bladder cancer based on positive Phase 3 VOLGA trial data.

Clinical Trial Data

Phase

Phase 3

Outcome Details

FDA granted priority review

Importance:7/10

Sentiment:

0.80

FDApriority reviewmuscle-invasive bladder cancerMIBCPhase 3perioperative

Related Companies

$AZN

Read the original article

Published by Cancer Network on September 25, 2026 4:00 PM

Read Original